Efficacy and safety analysis of a docetaxel-plus-trastuzumab regimen in patients with early-stage HER2-positive breast cancer: a retrospective single-arm study.

ABSTRACT:

Background

A regimen of weekly paclitaxel and trastuzumab (WPH) is the standard treatment for patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer but has certain limitations. Weekly hospital visits are burdensome for patients and increase healthcare resource use. Docetaxel is currently used in several chemotherapy regimens for HER2-positive breast cancer, such as four cycles of docetaxel and cyclophosphamide plus trastuzumab (TC4H) or THP (paclitaxel, trastuzumab plus pertuzumab), and its safety and efficacy have been well established. Therefore, for patients who cannot visit the hospital for treatment every week, we have implemented a 3-week docetaxel regimen to replace the weekly paclitaxel schedule for these early-stage HER2-positive

SUBMITTER: Yao J 

PROVIDER: S-EPMC11921364 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature